Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months

CONCLUSION: Protective hSBA titers initially declined but were retained by many subjects for 4 years irrespective of primary MenB-FHbp vaccination schedule. Boosting at 48 months after primary vaccination was safe, well tolerated, and induced immune responses indicative of immunological memory that persisted through 26 months. Booster vaccination during late adolescence may prolong protection against MenB disease.PMID:34215452 | DOI:10.1016/j.vaccine.2021.06.005

Source: Vaccine - July 3, 2021 Category: Allergy & Immunology Authors: Lars Østergaard Timo Vesikari Shelly D Senders Carl-Erik Flodmark Pavel Kosina Han-Qing Jiang Jason D Maguire Judith Absalon Kathrin U Jansen Shannon L Harris Roger Maansson Paul Balmer Johannes Beeslaar John L Perez Source Type: research